Mice lacking the mitochondrial exonuclease MGME1 develop inflammatory kidney disease with glomerular dysfunction.
Journal
PLoS genetics
ISSN: 1553-7404
Titre abrégé: PLoS Genet
Pays: United States
ID NLM: 101239074
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
15
12
2021
accepted:
05
04
2022
revised:
19
05
2022
pubmed:
10
5
2022
medline:
24
5
2022
entrez:
9
5
2022
Statut:
epublish
Résumé
Mitochondrial DNA (mtDNA) maintenance disorders are caused by mutations in ubiquitously expressed nuclear genes and lead to syndromes with variable disease severity and tissue-specific phenotypes. Loss of function mutations in the gene encoding the mitochondrial genome and maintenance exonuclease 1 (MGME1) result in deletions and depletion of mtDNA leading to adult-onset multisystem mitochondrial disease in humans. To better understand the in vivo function of MGME1 and the associated disease pathophysiology, we characterized a Mgme1 mouse knockout model by extensive phenotyping of ageing knockout animals. We show that loss of MGME1 leads to de novo formation of linear deleted mtDNA fragments that are constantly made and degraded. These findings contradict previous proposal that MGME1 is essential for degradation of linear mtDNA fragments and instead support a model where MGME1 has a critical role in completion of mtDNA replication. We report that Mgme1 knockout mice develop a dramatic phenotype as they age and display progressive weight loss, cataract and retinopathy. Surprisingly, aged animals also develop kidney inflammation, glomerular changes and severe chronic progressive nephropathy, consistent with nephrotic syndrome. These findings link the faulty mtDNA synthesis to severe inflammatory disease and thus show that defective mtDNA replication can trigger an immune response that causes age-associated progressive pathology in the kidney.
Identifiants
pubmed: 35533204
doi: 10.1371/journal.pgen.1010190
pii: PGENETICS-D-21-01644
pmc: PMC9119528
doi:
Substances chimiques
DNA, Mitochondrial
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1010190Déclaration de conflit d'intérêts
I have read the journal’s policy and the authors of this manuscript have the following competing interests. NGL is a scientific founder and holds stock in Pretzel Therapeutics, Inc. The other authors have no competing interests.
Références
EMBO Rep. 2020 Apr 3;21(4):e49799
pubmed: 32202065
Nat Commun. 2018 Mar 23;9(1):1202
pubmed: 29572490
Curr Opin Genet Dev. 2016 Jun;38:52-62
pubmed: 27065468
J Inherit Metab Dis. 2017 Jul;40(4):587-599
pubmed: 28324239
Cell Metab. 2021 Dec 7;33(12):2464-2483.e18
pubmed: 34800366
Crit Rev Biochem Mol Biol. 2020 Dec;55(6):509-524
pubmed: 32972254
Trends Biochem Sci. 2021 Oct;46(10):812-821
pubmed: 34088564
Behav Brain Res. 2018 Oct 15;352:187-196
pubmed: 28966146
Nucleic Acids Res. 2016 Jul 8;44(12):5861-71
pubmed: 27220468
Cell Metab. 2014 Dec 2;20(6):1069-75
pubmed: 25470551
Toxicology. 2017 Nov 1;391:54-63
pubmed: 28765055
Hum Mol Genet. 2014 Dec 1;23(23):6147-62
pubmed: 24986917
Nat Genet. 2001 Jul;28(3):223-31
pubmed: 11431692
Pediatr Nephrol. 2013 Mar;28(3):357-61
pubmed: 23233040
Kidney Int. 2017 Nov;92(5):1051-1057
pubmed: 28893420
Int J Mol Sci. 2021 Jun 16;22(12):
pubmed: 34208592
Nat Genet. 2013 Feb;45(2):214-9
pubmed: 23313956
Crit Rev Toxicol. 2009;39(4):332-46
pubmed: 19514917
J Cell Biol. 2018 May 7;217(5):1601-1611
pubmed: 29519802
Nat Genet. 2001 Jul;28(3):211-2
pubmed: 11431686
Nat Commun. 2018 Jun 27;9(1):2491
pubmed: 29950568
Hum Mol Genet. 2013 May 15;22(10):1983-93
pubmed: 23393161
Nat Commun. 2018 Apr 30;9(1):1727
pubmed: 29712893
Sci Adv. 2021 Jul 2;7(27):
pubmed: 34215584
Annu Rev Biochem. 2016 Jun 2;85:133-60
pubmed: 27023847
Curr Protoc Mouse Biol. 2013 Jun 01;3(2):69-100
pubmed: 26069059
Front Cell Dev Biol. 2021 Jul 27;9:720490
pubmed: 34386501
Eur J Med Genet. 2017 Oct;60(10):533-535
pubmed: 28711739
Am J Hum Genet. 2006 Jun;78(6):1026-34
pubmed: 16685652